menu
    • menu
    [{"orgOrder":0,"company":"N-Zyme Biomedical","sponsor":"LGM Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Fosamprenavir Sodium Alginate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"N-Zyme Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"N-Zyme Biomedical \/ LGM Pharma","highestDevelopmentStatusID":"4","companyTruncated":"N-Zyme Biomedical \/ LGM Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by N-Zyme Biomedical

    Menu

    N-Zyme Biomedical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            N-Zyme Biomedical

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            N-Zyme Biomedical

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosamprenavir Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : LGM Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            N-Zyme & LGM Pharma Develop World’s First Pepsin Inhibitor for Reflux Disease

                            Details : The collaboration aims to bring to market a first-in-class, pepsin inhibitor, fosamprenavir that is safe and effective for patients with LPR and/or persistent GERD symptoms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 18, 2024

                            Lead Product(s) : Fosamprenavir Sodium Alginate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : LGM Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth